drugset

drugset / Trial / NCT00540657

A Phase II Study of CCX282-B in Patients With Celiac Disease

NCT00540657 ↗

Phase 2 Completed 90 enrolled Amgen

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether CCX282-B is effective in mitigating the effects of gluten ingestion in patients with celiac disease

Timeline

Start: 2007-10
Primary completion: 2008-06
Completion: 2008-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	vercirnon	Small molecule	250 mg	—

Indications